ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2281

Tartrate-Resistant Acid Phosphatase Deficiency in the Predisposition to Systemic Lupus Erythematosus

Jie An1, Tracy A. Briggs2, Nalini Agrawal3, Alice Wiedeman4, Laurence Chaperot5, Joel Plumas5, Yanick J. Crow2 and Keith B. Elkon6, 1Division of Rheumatology, Department of Medicine & Immunology, University of Washington, Seattle, WA, 2Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 3Rheumatology, University of Washington, Seattle, WA, 4Department of Immunology, University of Washington, Seattle, WA, 5Inserm U823/Ujf/EFS, Immunobiology & Immunotherapy of Cancers, La Tronche, France, 6Rheumatology Box 356428, University of Washington, Seattle, WA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Interferons and osteopontin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose: The enzyme tartrate-resistant acid phosphatase (TRAP) is highly expressed in osteoclasts. One of the main substrates for TRAP in bone matrix is osteopontin (OPN).  Biallelic mutations in the gene, ACP5, that encodes TRAP, result in an immuno-osseous disease called spondyloenchondrodysplasia (SPENCD).  In addition to bone and neurological abnormalities, SPENCD patients also develop autoimmune disorders such as systemic lupus erythematosus (SLE). Of note, SPENCD patients demonstrate evidence of increased interferon-alpha (IFN-α) production in their blood. Since very little is known about the function of TRAP in immune cells, the objectives of our study were to determine whether OPN is a substrate for TRAP and to define the consequences of TRAP deficiency in immune cells.  

Methods: Co-localization of TRAP and OPN was determined by confocal microscopy and also by immunoprecipitation and western blot analysis (IP-western).  TRAP overexpression or knockdown was performed by transfection with cDNA or shRNA, respectively.  Expression of IFN-α and IFN signature genes (ISGs) were determined by enzyme-linked immunosorbent assay (ELISA) and quantitative PCR (qPCR).  Phosphatase activity was quantified by Biomol Green fluorimetry.

Results: We observed that TRAP co-localized with OPN in early endosomes and the Golgi in both primary macrophages as well as in plasmacytoid dendritic cells (pDC).  Co-localization was confirmed biochemically: following co-transfection of cDNAs encoding TRAP and OPN in 293 cells, we reciprocally co-immunoprecipitated TRAP and OPN as determined by western blots. Also, in macrophages, anti-TRAP antibody immunoprecipitated both TRAP and OPN, indicating that they interacted with each other in primary non-transfected cells.  To confirm that OPN was indeed a substrate for TRAP, we observed that recombinant human TRAP dephosphorylated OPN by the release of free phosphate in an in vitroassay.  To relate the functional significance of TRAP deficiency to IFN-α production, we knocked down the expression of TRAP in pDC.  We observed that TRAP specific shRNA, but not scrambled shRNA, increased the expression of IFN-α and IFN signature genes (ISGs). 

Conclusion: Taken together, these findings indicate that TRAP and OPN co-localize and that OPN is a substrate for TRAP in immune cells.  Significantly, TRAP deficiency in pDC leads to increased IFN-α production providing an explanation for why TRAP mutations lead to a lupus-like disease in SPENCD patients.


Disclosure:

J. An,
None;

T. A. Briggs,
None;

N. Agrawal,
None;

A. Wiedeman,
None;

L. Chaperot,
None;

J. Plumas,
None;

Y. J. Crow,
None;

K. B. Elkon,

Hoffman La Roche ,

5,

Resolve Therapeutics,

4.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tartrate-resistant-acid-phosphatase-deficiency-in-the-predisposition-to-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology